In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
In the past, scientists have overlooked the vascular system’s role in aging and dementia. But increasingly, research is showing that vascular dysfunction like damage…
Two large hospitals, Cleveland Clinic and Mount Sinai, have decided against administering Aduhelm for patients following controversy around the Alzheimer’s drug’s FDA approval drug…
This article is part of the series Diversity & Dementia, an editorially independent series produced by Being Patient with support provided by Eisai. One day, young Andres…
In the 1990s, the idea that clumps of beta-amyloid proteins are the main culprits of Alzheimer’s took off, and this line of thought —…
UPDATE: 3 March 2024, 8:22 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Following sharp criticisms of the FDA’s broad approval of Aduhelm for all patients with Alzheimer’s, the agency has narrowed the drug’s label to those…
Image: Lynn Casteel Harper, by Travis Tanay Lynn Casteel Harper, author of On Vanishing: Mortality, Dementia, and What It Means to Disappear (Catapult, 2020) and minister of…
Following a diagnosis of mild cognitive impairment, patients can find themselves in a state of limbo, caught between being cognitively normal and living with…
Image: Aduhelm, Biogen/AP. “The approach I’ve been taking is that each decision about whether or not to offer this as a treatment has to…
Whether it’s forgetting a name or where we placed our keys and cell phone, memory lapses can be especially worrying for aging adults with…
UPDATE: 3 March 2024, 8:26 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
For retired neurologist Daniel Gibbs, an Alzheimer’s diagnosis gave him not only a sense of relief, but a new lifestyle: one of healthier living,…
Retired neurologist Daniel Gibbs speaks about his own Alzheimer’s diagnosis, his unusual and severe case of side effects in aducanumab (Aduhelm) clinical trials, and…
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…